title: [Post-transplant lymphoproliferative disease in liver transplant recipients--Merkur University Hospital single center experience].
abstract: Post-transplant lymphoproliferative disorder (PTLD) is an increasingly recognized condition as the number of solid organ and bone marrow transplant recipients increases. It can be a life threatening fulminant disorder and affects approximately 8% of solid organ transplant recipients. Epstein-Barr virus (EBV) is closely involved in the pathogenesis of PTLD and the majority of PTLD cases arise in response to primary infection with EBV or to re-activation of previously acquired EBV. The principal risk factors underlying the development of PTLD are the degree of overall immunosuppression and EBV serostatus of the recipient. The most commonly used pathologic classification of PTLD is the World Health Organization classification, which divides PTLD into three categories: early lesions, polymorphic PTLD, and monomorphic PTLD. Early lesions are characterized by reactive plasmacytic hyperplasia. Polymorphic PTLD may be either polyclonal or monoclonal and is characterized by destruction of the underlying lymphoid architecture, necrosis, and nuclear atypia. In monomorphic PTLD, the majority of cases (>80%) arise from B cells, similar to non-Hodgkin's lymphoma in immunocompetent hosts. The most common subtype is diffuse large B-cell lymphoma, but Burkitt's/Burkitt's-like lymphoma and plasma cell myeloma are also seen. Rarely T-cell variants occur, which include peripheral T-cell lymphomas and, rarely, other uncommon types, including gamma/delta T-cell lymphoma and T-natural killer (NK) cell varieties. Hodgkin's disease-like lymphoma is very unusual. An accurate diagnosis of PTLD requires a high index of suspicion, since the disorder may present subtly and/or extranodally. Radiologic evidence of a mass or the presence of elevated serum markers (such as increased LDH levels) are suggestive of PTLD, with positive finding on ultrasonography, computed tomography, magnetic resonance and/or positron emission tomography scanning (possibly indicating metabolically active areas) also favoring the diagnosis. The management of PTLD poses a major therapeutic challenge and although there is reasonable agreement about the overall principles of treatment, there is still considerable controversy about the optimal treatment of individual patients. EBV-related PTLDs are a significant cause of mortality in patients undergoing orthotopic liver transplantation with the observed mortality rate of up to 50%. This paper presents the experience acquired at Merkur University Hospital in the diagnosis and treatment of patients with liver transplantation and PTLD.
authors.affiliation: Merkur University Hospital, Department of Internal Medicine, Division of Gastroenterology, Zagreb, Croatia. tajana_filipec@yahoo.com
authors.forename: Tajana
authors.initials: T
authors.lastname: Filipec-Kanizaj
authors.forename: Jelena
authors.initials: J
authors.lastname: Budimir
authors.forename: Vesna
authors.initials: V
authors.lastname: Colić-Cvrlje
authors.forename: Ika
authors.initials: I
authors.lastname: Kardum-Skelin
authors.forename: Dunja
authors.initials: D
authors.lastname: Sustercić
authors.forename: Slavica
authors.initials: S
authors.lastname: Naumovski-Mihalić
authors.forename: Anna
authors.initials: A
authors.lastname: Mrzljak
authors.forename: Slobodanka Ostojić
authors.initials: SO
authors.lastname: Kolonić
authors.forename: Nikola
authors.initials: N
authors.lastname: Sobocan
authors.forename: Tihomir
authors.initials: T
authors.lastname: Bradić
authors.forename: Zrinka Misetić
authors.initials: ZM
authors.lastname: Dolić
authors.forename: Branislav
authors.initials: B
authors.lastname: Kocman
authors.forename: Miroslava
authors.initials: M
authors.lastname: Katicić
authors.forename: Snjezana
authors.initials: S
authors.lastname: Zidovec-Lepej
authors.forename: Adriana
authors.initials: A
authors.lastname: Vince
mesh_terms: D000328:Adult; D005260:Female; D006801:Humans; D016031:Liver Transplantation / Q000009:adverse effects*; D008232:Lymphoproliferative Disorders / Q000145:classification / Q000175:diagnosis / Q000209:etiology* / Q000473:pathology; D008297:Male; D008875:Middle Aged